Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 2, 1996, Pages 298-301

  Klemens, S P ^a,b   Cynamon, M H ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFALAZIL; RIFAMYCIN; RIFAMYCIN DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; LUNG ALVEOLUS CELL; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SPLEEN CELL; TUBERCULOSIS;

EID: 0030071914     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.2.298     Document Type: Article

References (13)

1. American Thoracic Society. 1992. Control of tuberculosis in the United States Am. Rev. Respir Dis. 146:1623-1633.
2. Combs, D. L., R. J. O'Brien, and L. J. Geiter. 1990. USPHS tuberculosis short-course chemotherapy trial 21. effectiveness, toxicity, and acceptability. Ann. Intern. Med. 112:397-406.
3. Cynamon, M. H. 1985. Comparative in vitro activities of MDL-473, rifampin, and ansamycin against Mycobacterium intracellulare. Antimicrob. Agents Chemother. 28:440-441.
4. Ellner, J. J., A. R. Hinman, S. W. Dooley, M. A. Fischl, K. A. Sepkowitz, M. J. Goldberger, T. M. Shinnick, M. D. Iseman, and W. R. Jacobs, Jr. 1993. Tuberculosis symposium, emerging problems and promise J. Infect. Dis. 168:537-551
5. Hong Kong Chest Service/British Medical Research Council. 1991. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide Am. Rev Respir Dis 143:700-706.
6. Kirk, R. E. 1986. Experimental design, procedures for the behavioral sciences. Brooks-Cole Publishing Co., Belmont, Calif.
7. Klemens, S. P., M. A. Grossi, and M. H. Cynamon. 1994. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tubeculosis in a murine model Antimicrob. Agents Chemother. 38:2245-2248
8. Klemens, S. P., C. A. Sharpe, and M. H. Cynamon. 1994. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 38:1476-1479.
9. Kuze, F., T. Yamamoto, R. Amitani, and K. Suzuki. 1990. In vivo activities of new rifamycin derivatives against mycobacteria. Kekkaku 66:7-12.
10. Pittsfield Conference. 1986 Supplement on future research in tuberculosis: prospects and priorities for elimination Am. Rev. Respir. Dis. 134:401-423.
11. Saito, H., H. Tomioka, K. Sato, M. Emori, T. Yamane, K. Yamashita, K. Hosoe, and T. Hidaka. 1991 In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother. 35:542-547.
12. Yamamoto, T., R. Amitani, F. Kuze, and K. Suzuki. 1990. In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex. Kekkaku 65:31-36
13. Yamane, T., T. Hashizume, K. Yamashita, E. Konishi, K. Hosoe, T. Hidaka, K, Watanabe, H. Kawaharada, T. Yamamoto, and F. Kuze. 1993. Synthesis and biological activity of 3′-hydioxy-5′-aminobenzoxazinorifamycin derivatives. Chem. Pharm. Bull 41:148-155.